Nisa Investment Advisors LLC maintained its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,400 shares of the company’s stock at the end of the second quarter. Nisa Investment Advisors LLC’s holdings in Anika Therapeutics were worth $612,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of Anika Therapeutics by 165.8% in the first quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock worth $13,434,000 after buying an additional 187,400 shares during the period. Bogle Investment Management L P DE boosted its position in shares of Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock worth $4,962,000 after buying an additional 60,087 shares during the period. Fisher Asset Management LLC boosted its position in shares of Anika Therapeutics by 308.7% in the first quarter. Fisher Asset Management LLC now owns 57,719 shares of the company’s stock worth $2,792,000 after buying an additional 43,595 shares during the period. Panagora Asset Management Inc. boosted its position in shares of Anika Therapeutics by 965.7% in the first quarter. Panagora Asset Management Inc. now owns 30,234 shares of the company’s stock worth $1,352,000 after buying an additional 27,397 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Anika Therapeutics by 17.4% in the first quarter. Acadian Asset Management LLC now owns 173,771 shares of the company’s stock worth $7,771,000 after buying an additional 25,727 shares during the period. 77.85% of the stock is currently owned by institutional investors and hedge funds.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 0.19% during trading on Friday, hitting $47.37. The stock had a trading volume of 133,627 shares. Anika Therapeutics Inc. has a 12 month low of $30.93 and a 12 month high of $54.96. The stock has a market cap of $699.99 million, a price-to-earnings ratio of 20.68 and a beta of 1.50. The stock has a 50 day moving average price of $48.76 and a 200-day moving average price of $47.77.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, July 27th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. The firm earned $26.60 million during the quarter, compared to analyst estimates of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. The business’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.51 earnings per share. On average, equities analysts predict that Anika Therapeutics Inc. will post $2.00 EPS for the current year.

Separately, Zacks Investment Research raised Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price target on the stock in a research note on Monday, August 1st.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.